NeOnc Technologies Holdings, Inc.

NTHI ·Healthcare, Drug Manufacturers - General, United States
Financial Statements › Income Statement
Annual Quarterly

Income Statement

Line Item FY2025 FY2024
Revenue $40.0K $83.0K
Cost of Revenue — —
Gross Profit — —
Gross Margin — —
Operating Expenses
Research & Development $3.6M $3.0M
SG&A Expense $4.8M $1.7M
Operating Income $-58.2M $-7.1M
Operating Margin -145,637.5% -8,605.4%
Interest Expense $2.5M $2.6M
Pretax Income — —
Income Tax Expense — —
Net Income $-62.1M $-11.9M
Net Margin -155,404.4% -14,335.5%
EPS (Basic) $-3.20 $-0.69
EPS (Diluted) $-3.20 $-0.69
Shares Outstanding (Basic) 19.4M 17.3M
Shares Outstanding (Diluted) 19.4M 17.3M
Dividends Per Share — —